However, the authors reported that only pancreatic and renal cell carcinomas have showed moderate to strong and potentially clinically relevant GPER expression patterns [149], which projects that receptor as a potential diagnostic option or therapeutic target in these cancers. Here, GPER1 is linked to cancer.